Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

Prospective, Randomized, Active-controlled Investigator Initiated Clinical Trial to Demonstrate That the Nd:YAG/Er:YAG Dual Laser Therapy is Effective to Treat Vulvar Lichen Sclerosus and Similar to Standard Treatment With Steroid Cream

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT03926299
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-25T22:28:10.154184+00:00
Published At
2026-03-23T00:00:00+00:00
Record Updated At
2026-03-23
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Chronic Skin Disease", "Vulvar Lichen Sclerosus"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2026-03-23"
protocolSection.identificationModule.nctId
"NCT03926299"
protocolSection.identificationModule.officialTitle
"Prospective, Randomized, Active-controlled Investigator Initiated Clinical Trial to Demonstrate That the Nd:YAG/Er:YAG Dual Laser Therapy is Effective to Treat Vulvar Lichen Sclerosus and Similar to Standard Treatment With Steroid Cream"
protocolSection.statusModule.overallStatus
"COMPLETED"
protocolSection.designModule.phases
["NA"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
""

Study condition terms

  • Chronic Skin Disease (protocolSection.conditionsModule.conditions)
  • Vulvar Lichen Sclerosus (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.